메뉴 건너뛰기




Volumn 32, Issue 12, 2014, Pages 1249-1255

Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: A multi-institution study

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

EID: 84904764472     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.6055     Document Type: Article
Times cited : (28)

References (29)
  • 3
    • 79955478110 scopus 로고    scopus 로고
    • Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
    • Zhang S, Royer R, Li S, et al: Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 121:353-357, 2011
    • (2011) Gynecol Oncol , vol.121 , pp. 353-357
    • Zhang, S.1    Royer, R.2    Li, S.3
  • 4
    • 84864026311 scopus 로고    scopus 로고
    • BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group
    • Alsop K, Fereday S, Meldrum C, et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30:2654-2663, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 2654-2663
    • Alsop, K.1    Fereday, S.2    Meldrum, C.3
  • 5
    • 79959838081 scopus 로고    scopus 로고
    • Integrated genomic analyses of ovarian carcinoma
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
    • (2011) Nature , vol.474 , pp. 609-615
  • 6
    • 79251598279 scopus 로고    scopus 로고
    • Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
    • Vineyard MA, Daniels MS, Urbauer DL, et al: Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer? Gynecol Oncol 120:229-232, 2011
    • (2011) Gynecol Oncol , vol.120 , pp. 229-232
    • Vineyard, M.A.1    Daniels, M.S.2    Urbauer, D.L.3
  • 7
    • 81155152247 scopus 로고    scopus 로고
    • PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond
    • Banerjee S, Kaye S: PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 13:442-449, 2011
    • (2011) Curr Oncol Rep , vol.13 , pp. 442-449
    • Banerjee, S.1    Kaye, S.2
  • 8
    • 84856158117 scopus 로고    scopus 로고
    • Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
    • Bolton KL, Chenevix-Trench G, Goh C, et al: Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382-390, 2012
    • (2012) JAMA , vol.307 , pp. 382-390
    • Bolton, K.L.1    Chenevix-Trench, G.2    Goh, C.3
  • 9
    • 84863010984 scopus 로고    scopus 로고
    • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
    • Kaye SB, Lubinski J, Matulonis U, et al: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30:372-379, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 372-379
    • Kaye, S.B.1    Lubinski, J.2    Matulonis, U.3
  • 10
    • 84856731422 scopus 로고    scopus 로고
    • Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: Lessons learned from a negative trial
    • Konstantinopoulos PA, Cannistra SA: Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: Lessons learned from a negative trial. J Clin Oncol 30:347-350, 2012
    • (2012) J Clin Oncol , vol.30 , pp. 347-350
    • Konstantinopoulos, P.A.1    Cannistra, S.A.2
  • 11
    • 79955476362 scopus 로고    scopus 로고
    • Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
    • Lacour RA, Westin SN, Meyer LA, et al: Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. Gynecol Oncol 121:358-363, 2011
    • (2011) Gynecol Oncol , vol.121 , pp. 358-363
    • Lacour, R.A.1    Westin, S.N.2    Meyer, L.A.3
  • 12
    • 77449112281 scopus 로고    scopus 로고
    • Preventing future cancers by testing women with ovarian cancer for BRCA mutations
    • Kwon JS, Daniels MS, Sun CC, et al: Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 28:675-682, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 675-682
    • Kwon, J.S.1    Daniels, M.S.2    Sun, C.C.3
  • 14
    • 84873742602 scopus 로고    scopus 로고
    • Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing
    • Norquist BM, Pennington KP, Agnew KJ, et al: Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol 128:483-487, 2013
    • (2013) Gynecol Oncol , vol.128 , pp. 483-487
    • Norquist, B.M.1    Pennington, K.P.2    Agnew, K.J.3
  • 15
    • 37549072095 scopus 로고    scopus 로고
    • Genetic/Familial High Risk Assessment: Breast and Ovarian, V1
    • National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High Risk Assessment: Breast and Ovarian, V1.2012. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
    • (2012) NCCN Clinical Practice Guidelines in Oncology
  • 16
    • 60849136037 scopus 로고    scopus 로고
    • Accuracy of the BRCAPRO model among women with bilateral breast cancer
    • Ready KJ, Vogel KJ, Atchley DP, et al: Accuracy of the BRCAPRO model among women with bilateral breast cancer. Cancer 115:725-730, 2009
    • (2009) Cancer , vol.115 , pp. 725-730
    • Ready, K.J.1    Vogel, K.J.2    Atchley, D.P.3
  • 17
    • 0031917403 scopus 로고    scopus 로고
    • Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2
    • DOI 10.1086/301670
    • Parmigiani G, Berry D, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62:145-158, 1998 (Pubitemid 28093844)
    • (1998) American Journal of Human Genetics , vol.62 , Issue.1 , pp. 145-158
    • Parmigiani, G.1    Berry, D.A.2    Aguilar, O.3
  • 19
    • 65649118180 scopus 로고    scopus 로고
    • ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome
    • American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, et al
    • American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, et al: ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113:957-966, 2009
    • (2009) Obstet Gynecol , vol.113 , pp. 957-966
  • 23
    • 33646815890 scopus 로고    scopus 로고
    • BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
    • Antoniou AC, Durocher F, Smith P, et al: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8:R3, 2006
    • (2006) Breast Cancer Res , vol.8
    • Antoniou, A.C.1    Durocher, F.2    Smith, P.3
  • 24
    • 66649102437 scopus 로고    scopus 로고
    • Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: Findings from the Northern California Breast Cancer Family Registry
    • Kurian AW, Gong GD, John EM, et al: Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: Findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev 18:1084-1091, 2009
    • (2009) Cancer Epidemiol Biomarkers Prev , vol.18 , pp. 1084-1091
    • Kurian, A.W.1    Gong, G.D.2    John, E.M.3
  • 25
    • 84880298290 scopus 로고    scopus 로고
    • Keeping it simple: Genetics referrals for all invasive serous ovarian cancers
    • Demsky R, McCuaig J, Maganti M, et al: Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol Oncol 130:329-333, 2013
    • (2013) Gynecol Oncol , vol.130 , pp. 329-333
    • Demsky, R.1    McCuaig, J.2    Maganti, M.3
  • 26
    • 48949119472 scopus 로고    scopus 로고
    • Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction
    • Tai YC, Chen S, Parmigiani G, et al: Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 10:401, 2008
    • (2008) Breast Cancer Res , vol.10 , pp. 401
    • Tai, Y.C.1    Chen, S.2    Parmigiani, G.3
  • 27
    • 78149477590 scopus 로고    scopus 로고
    • Incorporating tumour pathology information into breast cancer risk prediction algorithms
    • Mavaddat N, Rebbeck TR, Lakhani SR, et al: Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12:R28, 2010
    • (2010) Breast Cancer Res , vol.12
    • Mavaddat, N.1    Rebbeck, T.R.2    Lakhani, S.R.3
  • 28
    • 52049087559 scopus 로고    scopus 로고
    • What women with ovarian cancer think and know about genetic testing
    • Lacour RA, Daniels MS, Westin SN, et al: What women with ovarian cancer think and know about genetic testing. Gynecol Oncol 111:132-136, 2008
    • (2008) Gynecol Oncol , vol.111 , pp. 132-136
    • Lacour, R.A.1    Daniels, M.S.2    Westin, S.N.3
  • 29
    • 83055184366 scopus 로고    scopus 로고
    • There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer
    • Meiser B, Gleeson M, Kasparian N, et al: There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. Gynecol Oncol 124:153-157, 2012
    • (2012) Gynecol Oncol , vol.124 , pp. 153-157
    • Meiser, B.1    Gleeson, M.2    Kasparian, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.